永安药业
(002365)
| 流通市值：33.97亿 | | | 总市值：40.75亿 |
| 流通股本：2.46亿 | | | 总股本：2.95亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 563,704,504.5 | 235,897,297 | 783,167,007.89 | 577,148,711.33 |
| 营业收入 | 563,704,504.5 | 235,897,297 | 783,167,007.89 | 577,148,711.33 |
| 二、营业总成本 | 505,141,633.94 | 226,434,212.68 | 791,244,833.8 | 586,972,011.53 |
| 营业成本 | 420,951,623.55 | 188,175,215.05 | 650,684,052.19 | 478,752,909.74 |
| 税金及附加 | 6,273,571.48 | 3,083,096.09 | 10,030,751.49 | 7,525,479.51 |
| 销售费用 | 17,139,491.76 | 9,228,146.66 | 40,065,902.58 | 31,798,297.87 |
| 管理费用 | 33,838,146.23 | 14,407,352.39 | 59,700,447.16 | 44,042,372.41 |
| 研发费用 | 20,815,527.35 | 8,622,162.46 | 30,876,613.76 | 26,082,917.32 |
| 财务费用 | 6,123,273.57 | 2,918,240.03 | -112,933.38 | -1,229,965.32 |
| 其中:利息费用 | 31,272.76 | 10,397.51 | 941,505.85 | 738,453.53 |
| 其中:利息收入 | 226,156.48 | 124,134.13 | 1,357,016.04 | 923,207.65 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,416,124.22 | -3,507,210.49 | -1,085,650.93 | 85,800.14 |
| 加:投资收益 | 9,315,453.45 | 5,242,302.15 | 30,560,208.94 | 25,322,485.07 |
| 资产处置收益 | 8,229.04 | -33,352.93 | 185,682.47 | 52,495.68 |
| 资产减值损失(新) | -3,242.04 | -3,242.04 | -16,527,392.86 | -822,527.84 |
| 信用减值损失(新) | -7,056,308.75 | -1,654,458.36 | 124,223.68 | 822,783.62 |
| 其他收益 | 1,237,938.43 | 647,764.19 | 5,470,623.02 | 2,599,789.12 |
| 四、营业利润 | 58,648,816.47 | 10,154,886.84 | 10,649,868.41 | 18,237,525.59 |
| 加:营业外收入 | 324,515.58 | 18,716.03 | 307,044.1 | 589,194.56 |
| 减:营业外支出 | 1,030,546.15 | 1,014,713.61 | 1,079,022.86 | 806,265.26 |
| 五、利润总额 | 57,942,785.9 | 9,158,889.26 | 9,877,889.65 | 18,020,454.89 |
| 减:所得税费用 | 15,157,843.71 | 1,170,176.54 | 2,687,825.14 | 1,678,334.1 |
| 六、净利润 | 42,784,942.19 | 7,988,712.72 | 7,190,064.51 | 16,342,120.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 42,784,942.19 | 7,988,712.72 | 7,190,064.51 | 16,342,120.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 43,408,294.2 | 7,736,703.46 | 22,493,429.92 | 25,496,259.56 |
| 少数股东损益 | -623,352.01 | 252,009.26 | -15,303,365.41 | -9,154,138.77 |
| 扣除非经常损益后的净利润 | 39,361,558.1 | 7,250,939.13 | -2,441,923.78 | 5,184,418.3 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.03 | 0.08 | 0.09 |
| (二)稀释每股收益 | 0.15 | 0.03 | 0.08 | 0.09 |
| 八、其他综合收益 | -232,563.76 | -114,894.12 | -170,283.48 | -86,818.37 |
| 归属于母公司股东的其他综合收益 | -232,563.76 | -114,894.12 | -170,283.48 | -86,818.37 |
| 九、综合收益总额 | 42,552,378.43 | 7,873,818.6 | 7,019,781.03 | 16,255,302.42 |
| 归属于母公司股东的综合收益总额 | 43,175,730.44 | 7,621,809.34 | 22,323,146.44 | 25,409,441.19 |
| 归属于少数股东的综合收益总额 | -623,352.01 | 252,009.26 | -15,303,365.41 | -9,154,138.77 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-17 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |